OTCMKTS:HLUYY - Lundbeck Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$67.16 +0.05 (+0.07 %)
(As of 05/23/2018 02:11 PM ET)
Previous Close$67.1150
Today's Range$67.16 - $67.16
52-Week Range$46.61 - $67.39
Volume129 shs
Average Volume1,773 shs
Market Capitalization$13.31 billion
P/E Ratio27.87
Dividend Yield1.42%
Beta-0.02

About Lundbeck (OTCMKTS:HLUYY)

Lundbeck logoH. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Denmark and internationally. Its products include Abilify Maintena, Brintellix/Trintellix, Cipralex/Lexapro, Northera, Onfi, Rexulti, Sabril, and Xenazine. The company offers pharmaceutical products for the treatment of Alzheimer's disease, depression, Parkinson's disease, Schizophrenia, alcohol dependence, anxiety, Bipolar I disorder, Epilepsy, Huntington's disease, and symptomatic neurogenic orthostatic hypotension. H. Lundbeck A/S sells its products to distributors of pharmaceuticals, pharmacies, and hospitals. The company was founded in 1915 and is headquartered in Valby, Denmark.

Receive HLUYY News and Ratings via Email

Sign-up to receive the latest news and ratings for HLUYY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Tobacco products
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:HLUYY
CUSIPN/A
Phone45-3630-1311

Debt

Debt-to-Equity RatioN/A
Current Ratio1.37
Quick Ratio1.15

Price-To-Earnings

Trailing P/E Ratio27.87
Forward P/E Ratio18.81
P/E Growth1.7

Sales & Book Value

Annual Sales$2.62 billion
Price / Sales5.11
Cash Flow$2.0108 per share
Price / Cash33.40
Book Value$9.30 per share
Price / Book7.22

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$398.58 million
Net Margins15.23%
Return on Equity27.73%
Return on Assets15.39%

Miscellaneous

EmployeesN/A
Outstanding Shares199,060,000

Lundbeck (OTCMKTS:HLUYY) Frequently Asked Questions

What is Lundbeck's stock symbol?

Lundbeck trades on the OTCMKTS under the ticker symbol "HLUYY."

How were Lundbeck's earnings last quarter?

Lundbeck (OTCMKTS:HLUYY) posted its earnings results on Wednesday, November, 4th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.16. The firm earned $547.05 million during the quarter, compared to the consensus estimate of $514.82 million. Lundbeck had a net margin of 15.23% and a return on equity of 27.73%. View Lundbeck's Earnings History.

When is Lundbeck's next earnings date?

Lundbeck is scheduled to release their next quarterly earnings announcement on Wednesday, May, 23rd 2018. View Earnings Estimates for Lundbeck.

Who are some of Lundbeck's key competitors?

Who are Lundbeck's key executives?

Lundbeck's management team includes the folowing people:
  • Mr. Anders Götzsche, Interim CEO, Exec. VP & CFO (Age 51)
  • Mr. Lars Bang, Exec. VP of Supply Operations & Engineering (Age 56)
  • Dr. Anders Gersel Pedersen, Exec. VP of R&D (Age 67)
  • Mr. Jacob Tolstrup, Exec. VP of Commercial Operations (Age 46)
  • Mr. Palle Holm Olesen, Chief Specialist of Investor Relations & VP of Investor Relations

Has Lundbeck been receiving favorable news coverage?

Press coverage about HLUYY stock has been trending somewhat positive recently, Accern reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Lundbeck earned a news impact score of 0.06 on Accern's scale. They also gave media stories about the company an impact score of 47.21 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Lundbeck?

Shares of HLUYY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lundbeck's stock price today?

One share of HLUYY stock can currently be purchased for approximately $67.16.

How big of a company is Lundbeck?

Lundbeck has a market capitalization of $13.31 billion and generates $2.62 billion in revenue each year.

How can I contact Lundbeck?

Lundbeck's mailing address is Ottiliavej 9 Valby, Copenhagen G7, 2500. The company can be reached via phone at 45-3630-1311 or via email at [email protected]


MarketBeat Community Rating for Lundbeck (HLUYY)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  99 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  180
MarketBeat's community ratings are surveys of what our community members think about Lundbeck and other stocks. Vote "Outperform" if you believe HLUYY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HLUYY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Lundbeck (OTCMKTS:HLUYY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Lundbeck in the last 12 months. There are currently 2 sell ratings for the stock, resulting in a consensus rating of "Sell."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: SellSellHoldHold
Consensus Rating Score: 1.001.001.501.50
Ratings Breakdown: 2 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Lundbeck (OTCMKTS:HLUYY) Consensus Price Target History

Price Target History for Lundbeck (OTCMKTS:HLUYY)

Lundbeck (OTCMKTS:HLUYY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/3/2018DNB MarketsDowngradeBuy ➝ SellView Rating Details
7/28/2017Deutsche BankDowngradeHold ➝ SellView Rating Details
4/12/2017Jefferies GroupDowngradeBuy ➝ HoldView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Lundbeck (OTCMKTS:HLUYY) Earnings History and Estimates Chart

Earnings by Quarter for Lundbeck (OTCMKTS:HLUYY)

Lundbeck (OTCMKTS:HLUYY) Earnings Estimates

2018 EPS Consensus Estimate: $3.30
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.81$0.81$0.81
Q2 20181$0.93$0.93$0.93
Q3 20181$0.90$0.90$0.90
Q4 20181$0.66$0.66$0.66

Lundbeck (OTCMKTS HLUYY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/23/2018        
11/8/2017Q3 2017$0.73$686.98 millionViewN/AView Earnings Details
8/9/2017Q2 2017$0.60$632.79 millionViewN/AView Earnings Details
5/10/2017Q1 2017$0.51$0.56$591.29 million$603.37 millionViewN/AView Earnings Details
2/8/2017Q4 2016$0.31$0.51$602.08 million$604.61 millionViewN/AView Earnings Details
11/2/2016Q3 2016$0.49$592.20 millionViewN/AView Earnings Details
8/24/2016Q2 2016$0.35$569.78 millionViewN/AView Earnings Details
5/11/2016Q1 2016$0.31$557.58 millionViewN/AView Earnings Details
11/4/2015Q3 2015$0.01$0.17$514.82 million$547.05 millionViewN/AView Earnings Details
5/6/2015Q1 2015$0.07$0.10$524.98 million$531.99 millionViewN/AView Earnings Details
2/5/2015Q4 2014($0.24)($0.16)$529.61 million$499.13 millionViewN/AView Earnings Details
11/5/2014Q3 2014$0.13$567.11 millionViewN/AView Earnings Details
8/7/2014Q2 2014$0.12$0.13$631.79 million$618.00 millionViewN/AView Earnings Details
5/7/2014Q1 2014$0.39$0.42$690.02 million$668.29 millionViewN/AView Earnings Details
2/6/2014Q4 2013$0.84$0.02$372.47 million$655.42 millionViewN/AView Earnings Details
11/6/2013Q3 2013$0.20$0.25$611.65 million$645.45 millionViewN/AView Earnings Details
8/7/2013Q2 2013$0.20($0.45)$619.51 millionViewN/AView Earnings Details
5/1/2013Q1 2013$0.68$0.81$711.20 million$804.51 millionViewN/AView Earnings Details
2/6/2013Q4 2012$0.68$0.13ViewN/AView Earnings Details
11/7/2012Q3 2012$0.68$0.37ViewN/AView Earnings Details
8/8/2012Q2 2012$0.40($0.07)ViewN/AView Earnings Details
5/2/2012Q1 2012$0.68$0.56ViewN/AView Earnings Details
2/8/2012Q4 2011$0.39$0.18ViewN/AView Earnings Details
11/9/2011Q3 2011$0.68$0.34ViewN/AView Earnings Details
8/10/2011Q2 2011$0.71$0.78ViewN/AView Earnings Details
5/4/2011Q1 2011$0.61$0.87ViewN/AView Earnings Details
11/3/2010Q3 2010$0.60ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Lundbeck (OTCMKTS:HLUYY) Dividend Information

Lundbeck pays an annual dividend of $0.95 per share, with a dividend yield of 1.41%.
Annual Dividend:$0.95
Dividend Yield:1.41%
Payout Ratio(s):26.61% (Based on This Year's Estimates)
28.11% (Based on Next Year's Estimates)
47.25% (Based on Cash Flow)
Dividend Payments by Quarter for Lundbeck (OTCMKTS:HLUYY)

Lundbeck (OTCMKTS:HLUYY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Lundbeck (OTCMKTS HLUYY) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 0.07%
Insider Trading History for Lundbeck (OTCMKTS:HLUYY)

Lundbeck (OTCMKTS HLUYY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Lundbeck (OTCMKTS HLUYY) News Headlines

Source:
DateHeadline
Lundbeck (HLUYY) Expected to Earn FY2018 Earnings of $3.57 Per ShareLundbeck (HLUYY) Expected to Earn FY2018 Earnings of $3.57 Per Share
www.americanbankingnews.com - May 21 at 1:26 AM
Lundbeck (HLUYY) Stock Rating Upgraded by Zacks Investment ResearchLundbeck (HLUYY) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 19 at 12:52 AM
Jefferies Group Comments on Lundbecks Q2 2018 Earnings (HLUYY)Jefferies Group Comments on Lundbeck's Q2 2018 Earnings (HLUYY)
www.americanbankingnews.com - May 18 at 7:30 AM
Reviewing ADOCIA (ADOCY) and Lundbeck (HLUYY)Reviewing ADOCIA (ADOCY) and Lundbeck (HLUYY)
www.americanbankingnews.com - May 14 at 10:14 AM
Lundbeck Thriving On Cost ControlLundbeck Thriving On Cost Control
seekingalpha.com - May 9 at 3:53 PM
Head to Head Survey: British American Tobacco (BTI) vs. Lundbeck (HLUYY)Head to Head Survey: British American Tobacco (BTI) vs. Lundbeck (HLUYY)
www.americanbankingnews.com - May 8 at 12:34 PM
H. Lundbeck Gets An Unexpected Boon From The FDAH. Lundbeck Gets An Unexpected Boon From The FDA
seekingalpha.com - May 5 at 10:31 AM
Lundbeck Gets An Unexpected Boon From The FDALundbeck Gets An Unexpected Boon From The FDA
seekingalpha.com - May 4 at 3:50 PM
Lundbeck (HLUYY) Lowered to "Sell" at DNB MarketsLundbeck (HLUYY) Lowered to "Sell" at DNB Markets
www.americanbankingnews.com - May 3 at 11:03 PM
Comparing Lundbeck (HLUYY) and Imperial Brands (IMBBY)Comparing Lundbeck (HLUYY) and Imperial Brands (IMBBY)
www.americanbankingnews.com - May 2 at 8:16 AM
Head to Head Survey: Lundbeck (HLUYY) versus Pharming Group (PHGUF)Head to Head Survey: Lundbeck (HLUYY) versus Pharming Group (PHGUF)
www.americanbankingnews.com - April 30 at 9:18 PM
Contrasting Lundbeck (HLUYY) & Indivior (INVVY)Contrasting Lundbeck (HLUYY) & Indivior (INVVY)
www.americanbankingnews.com - April 29 at 7:55 AM
The Drug Committee of Ministry of Health, Labour and Welfare in Japan has accepted a 2-year extension of market exclusivity of Lexapro®The Drug Committee of Ministry of Health, Labour and Welfare in Japan has accepted a 2-year extension of market exclusivity of Lexapro®
globenewswire.com - April 27 at 10:50 AM
Imperial Brands (IMBBY) vs. Lundbeck (HLUYY) Head-To-Head SurveyImperial Brands (IMBBY) vs. Lundbeck (HLUYY) Head-To-Head Survey
www.americanbankingnews.com - April 24 at 3:12 PM
Zacks Investment Research Lowers Lundbeck (HLUYY) to HoldZacks Investment Research Lowers Lundbeck (HLUYY) to Hold
www.americanbankingnews.com - April 11 at 10:25 AM
H. Lundbeck A/S- (HLUYY) Lowered to Hold at Zacks Investment ResearchH. Lundbeck A/S- (HLUYY) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 2:46 PM
Pfizers Rare Disease Candidate Meets Endpoint in Phase IIIPfizer's Rare Disease Candidate Meets Endpoint in Phase III
finance.yahoo.com - April 2 at 10:42 AM
H. Lundbeck A/S- (HLUYY) Lowered to "Hold" at Zacks Investment ResearchH. Lundbeck A/S- (HLUYY) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 12:43 PM
Pfizers Xtandi Label Expansion Filing Gets Priority ReviewPfizer's Xtandi Label Expansion Filing Gets Priority Review
finance.yahoo.com - March 20 at 3:45 PM
Global antidepressant drugs market revenue is expected to be majorly contributed by North America marketGlobal antidepressant drugs market revenue is expected to be majorly contributed by North America market
www.marketwatch.com - March 9 at 11:33 AM
4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio
finance.yahoo.com - February 28 at 10:15 AM
H. Lundbeck A/S- to Post FY2021 Earnings of $2.99 Per Share, Jefferies Group Forecasts (HLUYY)H. Lundbeck A/S- to Post FY2021 Earnings of $2.99 Per Share, Jefferies Group Forecasts (HLUYY)
www.americanbankingnews.com - February 12 at 9:40 AM
Q1 2018 Earnings Estimate for H. Lundbeck A/S- Issued By Jefferies Group (HLUYY)Q1 2018 Earnings Estimate for H. Lundbeck A/S- Issued By Jefferies Group (HLUYY)
www.americanbankingnews.com - February 9 at 8:26 AM
Global Ion Channel Modulators IndustryGlobal Ion Channel Modulators Industry
www.bizjournals.com - February 8 at 9:29 AM
Zacks Investment Research Upgrades H. Lundbeck A/S- (HLUYY) to "Strong-Buy"Zacks Investment Research Upgrades H. Lundbeck A/S- (HLUYY) to "Strong-Buy"
www.americanbankingnews.com - January 20 at 1:22 PM
H. Lundbeck A/S- Expected to Earn FY2018 Earnings of $2.95 Per Share (HLUYY)H. Lundbeck A/S- Expected to Earn FY2018 Earnings of $2.95 Per Share (HLUYY)
www.americanbankingnews.com - January 19 at 4:46 PM
H. Lundbeck A/S- Expected to Post FY2017 Earnings of $2.44 Per Share (HLUYY)H. Lundbeck A/S- Expected to Post FY2017 Earnings of $2.44 Per Share (HLUYY)
www.americanbankingnews.com - January 18 at 6:44 AM
Tevas Trisenox Gets FDA Approval as First-Line TreatmentTeva's Trisenox Gets FDA Approval as First-Line Treatment
www.zacks.com - January 16 at 10:08 AM
Pfizers Leukemia Drug Gets FDA Nod in First-Line SettingPfizer's Leukemia Drug Gets FDA Nod in First-Line Setting
finance.yahoo.com - December 20 at 3:57 PM
Pfizer Hikes Dividend, Announces $10B Share Buyback PlanPfizer Hikes Dividend, Announces $10B Share Buyback Plan
www.zacks.com - December 19 at 10:10 AM
H. Lundbeck A/S- (HLUYY) Upgraded by Zacks Investment Research to BuyH. Lundbeck A/S- (HLUYY) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - December 16 at 12:06 AM
H. Lundbeck A/S- (HLUYY) Downgraded by Zacks Investment Research to HoldH. Lundbeck A/S- (HLUYY) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - December 14 at 11:26 PM
Sanofi Wins FDA Approval for Biosimilar of Lillys HumalogSanofi Wins FDA Approval for Biosimilar of Lilly's Humalog
finance.yahoo.com - December 12 at 10:36 AM
AbbVie Psoriasis Candidate Succeeds in 4th Phase III StudyAbbVie Psoriasis Candidate Succeeds in 4th Phase III Study
www.nasdaq.com - December 5 at 12:45 PM
H Lundbeck A/S (HLUYY) Lifted to Buy at Zacks Investment ResearchH Lundbeck A/S (HLUYY) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - November 25 at 9:32 AM
U.S. FDA approves Carnexiv™ (carbamazepine) injection as intravenous replacement therapy for oral carbamazepine formulationsU.S. FDA approves Carnexiv™ (carbamazepine) injection as intravenous replacement therapy for oral carbamazepine formulations
globenewswire.com - October 8 at 5:07 PM
Headline conclusions from the first out of three phase III studies on idalopirdine in Alzheimer’s diseaseHeadline conclusions from the first out of three phase III studies on idalopirdine in Alzheimer’s disease
globenewswire.com - September 22 at 5:29 PM
The General Court of the EU upholds the European Commissions 2013 fining decision against LundbeckThe General Court of the EU upholds the European Commission's 2013 fining decision against Lundbeck
globenewswire.com - September 9 at 10:09 AM
Lundbeck increases its share capital by 97,349 shares (0.0493 % of outstanding shares) as a result of exercise of employee warrantsLundbeck increases its share capital by 97,349 shares (0.0493 % of outstanding shares) as a result of exercise of employee warrants
globenewswire.com - September 7 at 5:37 PM
Idalopirdine granted Fast Track Designation by U.S. Food and Drug Administration (FDA)Idalopirdine granted Fast Track Designation by U.S. Food and Drug Administration (FDA)
globenewswire.com - July 7 at 5:33 PM
Brexit Would Put EU Drug Regulator’s Headquarters in PlayBrexit Would Put EU Drug Regulator’s Headquarters in Play
www.wsj.com - June 17 at 8:12 AM
Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entitiesTransactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities
globenewswire.com - June 2 at 5:43 PM
Total number of voting rights and share capital in H. Lundbeck A/S as of 29 February 2016 - GlobeNewswire (press release)Total number of voting rights and share capital in H. Lundbeck A/S as of 29 February 2016 - GlobeNewswire (press release)
globenewswire.com - March 2 at 2:56 PM
H. Lundbeck A/S increases its share capital by 40104 shares (0.0203 % of outstanding shares) as a result of employee ... - GlobeNewswire (press release)H. Lundbeck A/S increases its share capital by 40104 shares (0.0203 % of outstanding shares) as a result of employee ... - GlobeNewswire (press release)
globenewswire.com - February 23 at 2:31 PM
H LUNDBECK A/SH LUNDBECK A/S
www.finanznachrichten.de - February 23 at 2:31 PM
European Stocks Drop More Than 1% on Weak EarningsEuropean Stocks Drop More Than 1% on Weak Earnings
www.thestreet.com - August 19 at 7:29 AM

SEC Filings

Lundbeck (OTCMKTS:HLUYY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Lundbeck (OTCMKTS HLUYY) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.